AustralianSuper Pty Ltd raised its stake in Becton Dickinson and Co (NYSE:BDX) by 2.9% in the third quarter, HoldingsChannel reports. The firm owned 17,500 shares of the medical instruments supplier’s stock after acquiring an additional 500 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Becton Dickinson and were worth $4,568,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of BDX. Acropolis Investment Management LLC bought a new position in shares of Becton Dickinson and during the 3rd quarter worth approximately $101,000. Almanack Investment Partners LLC. bought a new position in shares of Becton Dickinson and during the 2nd quarter worth approximately $105,000. Truvestments Capital LLC bought a new position in shares of Becton Dickinson and during the 3rd quarter worth approximately $105,000. Bartlett & Co. LLC boosted its stake in shares of Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after acquiring an additional 435 shares during the period. Finally, Bridgeworth LLC bought a new position in shares of Becton Dickinson and during the 2nd quarter worth approximately $131,000. Hedge funds and other institutional investors own 92.70% of the company’s stock.

Several research analysts have recently commented on the company. Citigroup reduced their target price on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a research note on Tuesday, November 13th. KeyCorp lifted their target price on Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday, November 8th. Barclays set a $260.00 target price on Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday, November 8th. Wells Fargo & Co reduced their target price on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Finally, Piper Jaffray Companies reduced their target price on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $253.79.

NYSE:BDX opened at $246.07 on Monday. The company has a market cap of $65.84 billion, a P/E ratio of 22.35, a PEG ratio of 1.69 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a 1-year low of $209.91 and a 1-year high of $265.87.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same period last year, the firm posted $2.40 EPS. As a group, equities research analysts forecast that Becton Dickinson and Co will post 12.15 earnings per share for the current year.

In related news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 16,866 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total value of $4,007,530.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,665 shares of company stock valued at $16,807,058. 1.00% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This story was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2018/11/19/australiansuper-pty-ltd-has-4-57-million-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: Return on Investment (ROI) Defined, Explained

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.